The global cardiac marker testing market was valued at USD 3.56 billion in 2023 and will grow by USD 5.45 billion by 2028. This market is showcasing a CAGR of 8.89% from 2023 to 2028.
Cardiac markers are used in treating and risk stratification patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers. These biomarkers can detect various heart disorders, including acute coronary syndrome, cardiac ischemia, and conditions involving obstructed blood flow to the heart. Physicians perform cardiac marker tests over several hours to keep track of the blood sugar increase and determine the severity of a heart attack.
Y-O-Y Growth in the aging population and growing funds by various organizations to encourage experiments and clinical trials in marker testing for examining the novel markers of the heart are the factors that propel the global cardiac marker testing market growth.
Increasing incidences of heart-related diseases and spending significantly on R&D activities are fuelling the market demand. Furthermore, the demand is expected to develop as people become more aware of the importance of early diagnosis and the growing need to prevent cardiac disorders like heart failure, heart attack, ACS, and others. In addition, increased coronary disease prevalence, an aging population, more clinical trials for cardiac biomarker detection, and increased support from public-private organizations for cardiac biomarker studies drive the cardiac marker testing market.
Additionally, Growth in point-of-care testing and growing demand for the latest treatment procedures are the factors that are accelerating the market. Also, increasing awareness of the benefits of early diagnosis and preventing heart diseases like heart attacks are driving market growth. Furthermore, the rising need to advance healthcare services and rising healthcare expenditure and disposable incomes in developing countries are pushing market growth.
Unfavorable reimbursement policies and stringent rules and regulations by the government are the factors that are hampering the global cardiac marker testing market growth. The cardiac markers are not used for diagnosing the myocardial blood supply to the heart or the tissue region that causes death. In addition, problems related to storage and preservation of sample collection and the amount paid for the cause of suffering are restraining the Growth. Factors like correct and early outcomes and cardiac POC testing are the factors that drive market growth.
COVID-19 impact on the global cardiac marker testing market:
The highly infectious extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19), which has resulted in a global outbreak. The cardiac marker testing market has also experienced short-term negative Growth, which can be due to factors like a more than fifty percent decrease in the number of patients with cardiovascular diseases and those diagnosed with myocardial infarction. Traditional biomarkers of heart failure, such as cardiac markers and B-type natriuretic peptides (BNP), are increased in patients with COVID-19 due to the pandemic outbreak of the SARS-CoV-2 virus and novel coronavirus disease 2019 (COVID-19). All areas of cardiology service provision, including outpatient hospitals, investigations, treatments, and cardiology community services, including cardiac rehabilitation, experienced significant reductions. COVID-19 has several effects on the cardiovascular system. Inflammation, multi-organ interaction, and evidence of heart stress and disease describe COVID-19, a systemic infection. COVID-19 patients with chronic or coronary heart disease have a higher percentage of abnormal cardiac markers and a higher mortality and ICU admission rate. In COVID-19 patients with or without pre-existing coronary artery disease, BNP, along with his-TNI, - HBDH, CK-MB, and LDH, acts as a prognostic biomarker. Considering all these factors, Cardiac Marker Testing Market has had moderate Growth during this pandemic and is expected to have more demand in the coming years.
Market Size Available
2022 to 2028
2023 to 2028
By Type, Product, Disease, Testing, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global cardiac marker testing market has been segmented and sub-segmented based on type, product, disease, testing, and region.
Cardiac Marker Testing Market - By Type:
Troponin I & T
Based on type, the troponin cardiac biomarkers segment is forecasted to lead the global cardiac marker testing market during the forecast period due to its efficiency and accuracy in test results to diagnose cardiovascular disorders. In addition, the segment is also leading the revenue due to professionals' familiarity with the segment.
However, the BNP segment is expected to show fast Growth during the forecast period due to its increasing usage for detecting heart damage and stress. Additionally, many enterprises are now taking initiatives to make cardiac marker testers of this type, further promoting the segment's Growth.
Cardiac Marker Testing Market – By Product:
The reagent segment is expected to dominate the market during the forecast period due to its applications in vitro test kits and laboratories. In addition, the reagents are a significant part of the research and development of cardiac diseases and drugs and help build a better future for the markers.
The instruments segment, however, is also expected to grow during the forecast period due to the rising need for cardiac diagnostic and treatment devices in healthcare settings. For example, cardiac marker analyzers are used to provide point-of-care solutions supporting the segment's establishment.
Cardiac Marker Testing Market – By Disease:
Acute Coronary Syndrome
Congestive Heart Failure
Based on disease, myocardial infarction is one of the fastest-growing segments, credited to its increase in the rate of sedentary lifestyle among individuals, alcohol consumption, smoking, and unhealthy food habits, resulting in obesity.
However, the congestive heart failure segment is also expected to show significant Grogrowthring the forecast period due to the rising cases of the problem. According to statistics, nearly 6 million Americans and around 670,000 people are diagnosed with heart failure yearly. Therefore, the prevalence of the disease is helping the market grow.
Cardiac Marker Testing Market – By Testing:
Based on testing, the laboratory testing segment is predicted to lead the global cardiac marker testing market. The rising research and development in the field of cardiac market testing from biotechnological, pharmaceutical and healthcare device companies are boosting the revenue of the segment.
However, The point-of-care testing segment offers the highest growth rate in this market segment. It can be credited to the availability of easy-to-use kits in ambulances, and affordability for patients at the point-of-care diagnostic tool reduces hospital expenditure, thereby increasing the adoption rate of new diagnostic tools.
Cardiac Marker Testing Market – By Region:
The Middle East and Africa
The North American market is predicted to hold the largest share of the global cardiac marker testing market, followed by Europe during the forecast period. Because of the prevalence of cardiovascular disorders, public and private investments, NIH funding for creating novel cardiac biomarkers, and the growing geriatric population, North America is expected to be the largest market. Furthermore, government and research institute measures to fight critical cardiac diseases and increase R&D activities related to cardiac biomarkers, driving market growth in North America.
However, the Asia-Pacific market is to register the highest gGrgrowthe to emerging markets, including India and China, which have become attractive destinations for companies engaged in developing and marketing cardiac biomarkers. The rising prevalence and incidence of cardiovascular diseases are among the major driving factors for the market growth in China and India. In addition, increased healthcare spending by a more extensive population base, transformation of healthcare facilities, and the penetration of clinical laboratory technology is driving the Asia-Pacific market. Along with this, demand in Asia-Pacific is expected to expand due to an increase in research-based pharmaceutical companies interest in developing novel biomarkers and increasing the number of patients suffering from cardiovascular diseases.
KEY MARKET PARTICIPANTS:
Some of the notable companies dominating the global cardiac marker testing market profiled in the report are Getinge Group, Medtronic PLC, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, Siemens AG, Danaher Corporation, Alere Inc., bioMérieux SA, LSI Medience Corporation, Ortho Clinical Diagnostics, Randox Laboratories Ltd and Guangzhou Wondfo Biotech Co. Ltd.
RECENT MARKET HAPPENINGS:
In May 2022, Quidel Corporation, a significant healthcare diagnostic devices manufacturer, developed a cardiac triage panel to support emergency heart cases at the ED. The device aids in diagnosing myocardial infarction and has been approved by the FDA for use. The device eradicates the uncertainty of results from an EKG in an emergency and helps enhance point-of-care diagnosis.
In October 2022, the biopharmaceutical enterprise bridge pharma announced the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i) 12 months results along with its partner ML bio solutions.
In October 2022, A study from BioRegenex, a regenerative therapeutics company with microvascular health solutions, revealed that people with obesity risk contracting cardiovascular diseases. Using GlycoCheck, an FDA-registered Class 1 medical testing device, the study proved that patients with obesity were at a higher risk of cardiac problems.
Getinge Group, Medtronic PLC, LivaNova PLC, XENIOS Roche Diagnostics Ltd., Abbott Laboratories, and Siemens AG, are some of the key players in the global cardiac marker testing market.
The global cardiac marker testing market is expected to grow at a CAGR of 8.89% during the forecast period.
The North American market is predicted to hold the largest share of the global cardiac marker testing market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]